Ovid Therapeutics Inc.

OVID

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001636651

SEC filings (opens in a new tab)

No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Ovid Therapeutics Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022 All holders in Q1 2022

13F holders of OVID: Q1 2022 compared with Q2 2022
Measure	Q1 2022	Q2 2022	Change
Holders	62	55	−7
Shares	35.1M	34.6M	−500.5K (−1.4%)
Value	$110.3M	$74.5M	−$35.9M (−32.5%)

New holders (7)

Institutions that held Ovid Therapeutics Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to OVID in Q2 2022
Institution	Shares	Value	% of portfolio
Rubric Capital Management LP	2,882,706	$6.20M	0.33%
Oasis Management Co Ltd.	68,800	$148.0K	0.03%
Assenagon Asset Management S.A.	26,362	$57.0K	0.00%
Squarepoint Ops LLC	10,543	$23.0K	0.00%
Cannell Capital LLC	5,949	$13.0K	0.00%
The PNC Financial Services Group, Inc.	2,000	$4.00K	0.00%
Simplex Trading, LLC	99	$0	0.00%

Sold out (14)

Institutions that held Ovid Therapeutics Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of OVID in Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
Globeflex Capital L P	1,305,588	$4.10M
Susquehanna International Group, LLP	307,874	$967.0K
Boothbay Fund Management, LLC	71,489	$224.0K
Man Group plc	47,863	$150.0K
O'Shaughnessy Asset Management, LLC	42,028	$132.0K
Citadel Advisors LLC	38,265	$120.0K
Dimensional Fund Advisors LP	19,564	$61.0K
Mirabella Financial Services LLP	19,500	$61.0K
Caxton Associates LP	17,386	$55.0K
Newman Dignan & Sheerar, Inc.	15,522	$49.0K
Stokes Family Office, LLC	15,246	$48.0K
Royce & Associates LP	11,811	$37.0K
Royal Bank of Canada	960	$3.00K
Concord Wealth Partners	210	$1.00K